Market Research Report
Global Human Milk Oligosaccharides Market - 2021-2028
|Global Human Milk Oligosaccharides Market - 2021-2028|
Published: July 5, 2021
Content info: 180 Pages
Delivery time: 2 business days
Human milk oligosaccharides (HMO) are present in human milk in the form of a complex bioactive sugar molecule. HMOs are growth substrates for certain useful bacteria. Extracting or synthesizing HMO in the formula is quite difficult as they are structurally diverse and complex. The human milk oligosaccharides (HMO) products available in the market are quite expensive as a huge quantity of human milk is synthesized just to obtain a small amount of HMO. Increasing concerns among consumers regarding gut health and the growing consumption of dietary supplements are expected to drive the growth. The global human milk oligosaccharides market valued USD XX million in 2020 and is forecasted to reach USD XX million by 2028, growing at a CAGR of XX% during the forecast period (2021-2028)
In the recent past, infant formula ingredients such as human milk oligosaccharides have become popular as an ingredient in the infant formula to meet the demands of the baby nutrition segment. Health benefits associated with the consumption of human milk oligosaccharides include maintaining gut microbiota and inhibition of pathogen in infants. China accounts for 30% of the global consumption of Infant formula which is followed by other Asian countries holding 28% of the market. About 65% of the growth in Infant formula market comes from China. In the United States, the HMO's intended for use in food other than dietary supplements are regulated under GRAS. In U.S CARE4U™ by DuPont was approved as GRAS, for use in infant formula and toddler foods. With the increasing demand for HMOs, in 2018, two HMO's have gone through the novel food safety assessment in Europe, with a positive assessment outcome and approval by the European Commission. In addition, due to the prebiotic functions and the antimicrobial protection of HMOs, they are increasingly used as a useful ingredient in products such as medicinal food, pharmaceutical, and infant formulas, thus driving the growth of the human milk oligosaccharides (HMO) market.
However, high cost associated with HMO products is expected to act as a restraint for the market growth. For example, expensive substrates such as glycosyl transferases require enzyme synthesis and this is one of the main factors attributable to the high pricing of human milk oligosaccharides. Prebiotics in infant formula, such as fructooligosaccharides and galactooligosaccharides, are used to inhibit the development of pathogenic Escherichia coli. Consumption of these has been shown to improve the health of infants' gastrointestinal tracts by promoting the development of specific microorganisms in the intestinal microflora. Owing to their low cost and wide availability, these are being used as a replacement for human milk oligosaccharides by infant formula manufacturers. As a result, these functionally equivalent alternatives to human milk oligosaccharides are severely limiting the overall market's expansion.
3' FL plays an important role in the development of gut microbiota in both adults and infants. The Nestle Nutrition Institute, in a study, stated that HMO concentrations change during different stages of lactation with different types showing different dynamics. Products such as 6'SL or LNT decrease more rapidly within the first weeks of lactation, although, for example, 2'FL and 3'SL decrease more slowly over a longer period of time and again others, such as 3FL, actually increase concentration with time of lactation. In November 2019, DuPont Nutrition & Biosciences applied for a patent for the use of 3'-FL as a novel food.
2'-Fucosyllactose is poised to grow with the fastest CAGR of XX% in the forecast period 2021-2028 as dietary supplement manufacturers shift to 2'-Fucosyllactose, since it is capable of altering gut microbiota composition and behavior from formula-powered infants receiving additional feeding, and its contribution to healthy digestion.
By geography, North America is expected to dominate the human milk oligosaccharides (HMO) market. North America has registered increased demand for donor human milk. On the other hand, there exist only 11 milk banks in countries such as Canada and the U.S., which is actually not sufficient to meet the increasing demand for donor milk. This factor will increase the usage of HMO in the infant formula in order to provide proper nutrition to the babies.
Asia Pacific is expected to grow with a CAGR of XX% during the forecast period. According to the WHO, in the next 10 years, the overall world population is expected to rise by about one billion and reach 9.5 billion by 2050. The constantly growing population is likely to increase demand for infant nutrition products in the Asia Pacific especially in countries like China and India owing to the high infant population. Moreover, rising concerns regarding gut diseases, high blood pressure, diabetes, and rickets among other chronic diseases have resulted in an increased demand for functional food and beverages, which is expected to propel the regional demand for human milk oligosaccharides.
The global human milk oligosaccharides (HMO) market is fragmented. The most active companies across the globe are BASF Corporation, DuPont Nutrition, and Health, ZuChem Inc. and Jennewein Biotechnologie GmbH among others. They have been expanding their geographical presence by acquiring or merging with the manufacturers in the foreign market. For instance, in February 2019, Jennewein Biotechnologie GmbH, a Germany-based functional sugars manufacturer, partnered with Yili.Com Inc., a China-based dairy products manufacturer, to research on infant microbiome and human milk oligosaccharides. This strategy was intended to develop innovative, HMO-based infant formula and was targeted at customers in China. Such developments/strategies are likely to surface over the forecast period, given the rising competition in the market. In May 2019, Glycosyn LLC and BASF SE signed an agreement for the development and commercialization of HMOs for widespread use in dietary supplements, functional nutrition, and medical food. As part of the collaboration and under the exclusive license, BASF SE will extend its offering of the most abundant HMO, 2'-Fucosyllactose (2'-FL) branded PREBILACTM, to emerging markets.
A robust and diverse food supply is an essential part of the health and nutrition response to COVID-19. The demand for nutraceuticals & functional foods is expected to witness an upward surge owing to consumers opting for immunity boosting supplements during the COVID-19 pandemic. The use of HMOs in dietary supplements offer benefits such as immune support, protection against bacterial and viral infections, digestive comfort, and brain function support. Furthermore, a decline in the consumption of poultry, meat and seafood products across the globe is expected to increase the demand for plant and animal-based protein supplements in the near future.